NuVasive (NUVA) Tops Q1 EPS by 2c

NuVasive (NASDAQ: NUVA) reported Q1 EPS of $0.37, $0.02 better than the analyst estimate of $0.35. Revenue for the quarter came in at $271.2 million versus the consensus estimate of $261.77 million.

"NuVasive delivered year-over-year growth in the U.S. and international markets, and I am encouraged by the continued recovery of elective surgical procedures and momentum in the business," said J. Christopher Barry, chief executive officer of NuVasive. "Our commitment to R&D investment furthers our ability to deliver the strongest innovation pipeline in spine that drives proceduralization across all spine segments. The positive surgeon feedback on NuVasive's acquisition of Simplify Medical, the Simplify Disc's recent FDA approval for two-level cervical total disc replacement, and the upcoming Pulse platform launch reinforces our dedication to outcome driven innovation that benefits the surgeon, provider, and - most importantly - the patient."

For earnings history and earnings-related data on NuVasive (NUVA) click here.

You May Also Be Interested In

• Genco rejects Diana Shipping bid, calls offer below NAV
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
• Movano (MOVE) Misses Q2 EPS by 195c